Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Default user image.

Crister Ceberg

Professor

Default user image.

Boron neutron capture therapy for glioblastoma multiforme : Clinical studies in Sweden

Författare

  • J Capala
  • BH Stenstam
  • KS Skold
  • Per Munck af Rosenschöld
  • V Giusti
  • C Persson
  • E Wallin
  • A Brun
  • L Franzen
  • JO Carlsson
  • Leif Salford
  • Crister Ceberg
  • Bertil R Persson
  • L Pellettieri
  • R Henriksson

Summary, in English

A boron neutron capture therapy (BNCT) facility has been constructed at Studsvik, Sweden. It includes two filter/moderator configurations. One of the resulting neutron beams has been optimized for clinical irradiations with a filter/moderator system that allows easy variation of the neutron spectrum from the thermal to the epithermal energy range. The other beam has been designed to produce a large uniform field of thermal neutrons for radio-biological research. Scientific operations of the Studsvik BNCT project are overseen by the Scientific Advisory Board comprised of representatives of major universities in Sweden. Furthermore, special task groups for clinical and preclinical studies have been formed to facilitate collaboration with academia. The clinical Phase II trials for glioblastoma are sponsored by the Swedish National Neuro-Oncology Group and, presently, involve a protocol for BNCT treatment of glioblastoma patients who have not received any therapy other than surgery. In this protocol, p-boronophenylalanine (BPA), administered as a 6-h intravenous infusion, is used as the boron delivery agent. As of January 2002, 17 patients were treated. The 6-h infusion of 900 mg BPA/kg body weight was shown to be safe and resulted in the average blood-boron concentration of 24 μg/g (range: 15-32 μg/g) at the time of irradiation (approximately 2-3 h post-infusion). Peak and average weighted radiation doses to the brain were in the ranges of 8.0-15.5 Gy(W) and 3.3-6.1 Gy(W), respectively. So far, no severe BNCT-related acute toxicities have been observed. Due to the short follow-up time, it is too early to evaluate the efficacy of these studies.

Avdelning/ar

  • Medicinsk strålningsfysik, Lund
  • Neurokirurgi

Publiceringsår

2003

Språk

Engelska

Sidor

135-144

Publikation/Tidskrift/Serie

Journal of Neuro-Oncology

Volym

62

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

Springer

Ämne

  • Surgery
  • Radiology, Nuclear Medicine and Medical Imaging
  • Neurology

Nyckelord

  • boronophenylalanine
  • glioblastoma multiforme
  • radiation therapy
  • boron neutron capture therapy
  • BNCT
  • clinical
  • trials

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1573-7373